Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia

Frontiers in Pediatrics

Pediatrics

Hongjun Liu¹  Tianping Chen¹  Wenxiu Lv²  Bo Zhang³  Fang Cao³  Shen Wang³  Chun Li³  Liang Wang³  Jing Wang³  Fang Xv³  Li Chen³  Na Li³  Chenglin Liao³ 

[1] Department of Hematology and Oncology, Anhui Provincial Children's Hospital (Anhui Hospital, Pediatric Hospital of Fudan University), Hefei, Anhui, China;Department of Hematology and Oncology, Anhui Provincial Children's Hospital (Anhui Hospital, Pediatric Hospital of Fudan University), Hefei, Anhui, China;Department of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China;Department of Pediatrics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China;

关键词: pediatric;    high-throughput drug sensitivity screening;    hematopoietic stem cell transplantation (HCST);    relapsed/refractory;    acute myeloid leukemia;   

DOI  :  10.3389/fped.2023.1117988

 received in 2022-12-07, accepted in 2023-01-23,  发布年份 2023

来源: Frontiers

【 摘 要 】

Relapsed/refractory (rel/ref) acute myeloid leukemia (AML) has a very high mortality rate. At present, hematopoietic stem cell transplantation (HSCT) is the most effective treatment for rel/ref AML. The remission of the primary disease before HSCT is crucial for the transplantation to be effective. Therefore, it is critical to choose a suitable type of chemotherapy before HSCT. Here, we recorded the outcomes of high-throughput drug sensitivity screening (HDS) in children with rel/ref AML. Thirty-seven pediatric rel/ref AML patients who received HDS from September 2017 until July 2021 were analyzed retrospectively. Most of the patients (24 patients, 64.9%) had adverse cytogenetics. Two patients had rel/ref AML with central nervous system leukemia. The complete remission (CR) rate was 67.6%. Eight patients developed IV grade bone marrow suppression. Twenty-three patients (62.2%) underwent HSCT. The 3-year overall survival (OS) and EFS rates were 45.9% and 43.2%, respectively. Infection in the myelosuppression stage was the main cause of death. The outcome of HDS was superior to the commonly reported rates. These results suggest that HDS may be a novel treatment option for pediatric patients with rel/ref AML, and it is a promising transitional regimen prior to HSCT.

【 授权许可】

Unknown   
© 2023 Lv, Chen, Wang, Li, Zhang, Wang, Xv, Cao, Wang, Chen, Liao, Li and Liu.